Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1259 - Risk of health-related quality of life events and pulmonary toxicities in recurrent ovarian cancer patients treated with poly adenosine diphosphate ribose polymerase (PARP) inhibitors maintenance

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Kyaw Thein

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

K.Z. Thein1, A. Sultan1, M.H. Zaw2, M.M. Han3, N.H. Yu4, H.P. Igid1, C. Jones1, N. D'Cunha1, S. Awasthi1, F. Hardwicke1

Author affiliations

  • 1 Hematology Oncology, Texas Tech University Health Sciences Center, 79430 - Lubbock/US
  • 2 Internal Medicine, The Brooklyn Hospital Center, Brooklyn/US
  • 3 Oncologic Emergency, The University of Texas MD Anderson Cancer Center, Houston/US
  • 4 Internal Medicine, Kingsbrook Jewish Medical Center, Brooklyn/US
More

Resources

Abstract 1259

Background

Pain and fatigue are the major determinants of health-related quality of life (HRQOL) in cancer patients undergoing chemotherapy. Ovarian cancer is the seventh most common cause of cancer in women worldwide. PARP inhibitors maintenance has shown to improve survival in recurrent ovarian cancer patients with notable toxicities. We undertook a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of HRQOL events and pulmonary toxicities.

Methods

We conducted a comprehensive literature search using MEDLINE, EMBASE databases and meeting abstracts from inception through March 2018. Phase III RCTs that mention HRQOL events and pulmonary toxicities as adverse effects were incorporated in the analysis. Mantel-Haenszel (MH) method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI). Fixed effects model was applied.

Results

Three phase III RCTs with a total of 1401 patients with recurrent ovarian cancer were eligible. The study arms used olaparib or niraparib or rucaparib while the control arms utilized placebo. The randomization ratio was 2:1 in all studies. The RR of all-grade side effects were as follows: fatigue, 1.54 (95% CI: 1.37 – 1.73, P < 0.001); back pain, 0.93 (95% CI: 0.70 – 1.24, P = 0.64); arthralgia, 1.05 (95% CI: 0.79 – 1.40, P = 0.69); headache, 1.75 (95% CI: 1.34 – 2.29, P < 0.001); decreased appetite, 1.76 (95% CI: 1.36 – 2.28, P < 0.001); cough, 1.87 (95% CI: 1.33 – 2.63, P < 0.001); dyspnea, 2.39 (95% CI: 1.64 – 3.48, P < 0.001); and upper respiratory infections (URI), 1.71 (95% CI: 1.16 – 2.53, P = 0.007). The RR of high-grade side effects were as follows: fatigue, 3.94 (95% CI: 1.90 – 8.17, P < 0.001); back pain, 0.49 (95% CI: 0.10 – 2.48, P = 0.39); arthralgia, 2.00 (95% CI: 0.22 – 17.82, P = 0.53); headache, 1.00 (95% CI: 0.18 – 5.47, P = 0.99); decreased appetite, 1.16 (95% CI: 0.17 – 7.82, P = 0.87); and dyspnea, 1.28 (95% CI: 0.30 – 5.48, P = 0.73).

Conclusions

Our study showed that the risk of developing any-grade headache, decreased appetite, cough, dyspnea and URI as well as all grades of fatigue with PARP inhibitors was high. Prompt intervention with good supportive care is required.

Clinical trial identification

Legal entity responsible for the study

Kyaw Zin Thein, Texas Tech University Health Sciences Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.